Oxford BioMedica publishes 2025 annual report and accounts

  • Oxford BioMedica published annual report for fiscal 2025, highlighting execution of its pure-play viral vector CDMO strategy.
  • Commercial momentum strengthened, with contracted client orders reaching about GBP 220 million.
  • US expansion advanced through acquisition of FDA-approved commercial-scale viral vector facility in Durham, North Carolina for about USD 4.5 million.
  • Client mix continued to diversify, with AAV accounting for more than half of new client wins.
  • Balance sheet reinforced through equity raise of about GBP 60 million, supporting planned investment across multi-site manufacturing network.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oxford BioMedica plc published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.